HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma (PROCLIVITY 02)

This study has been terminated.
(A shift in the melanoma treatment landscape adversely affected accrual & early closure)
M.D. Anderson Cancer Center
Johns Hopkins University
Information provided by (Responsible Party):
Prometheus Laboratories
ClinicalTrials.gov Identifier:
First received: May 10, 2013
Last updated: July 15, 2015
Last verified: July 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2015
  Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)